by inpharmedia | Jan 3, 2025 | Approvals, Blog, Regulatory
The FDA granted 50 new drug approvals in the year 2024 with several first-in-class, novel therapies and pathbreaking innovations spanning key therapy areas like oncology, gene therapy, immunology, hematology and cardiology. The U.S. Food and Drug Administration (FDA)... by inpharmedia | Mar 25, 2024 | Guidances, Regulatory
✅ What is Orphan Drug Designation Under the Orphan Drug Act and associated regulations (21 CFR §316), the FDA may designate a drug or biological product as an “orphan drug” if it is intended to treat, diagnose or prevent a “rare disease or condition” (affecting fewer... by inpharmedia | Jan 24, 2024 | Guidances, Regulatory
FDA published a new guidance in support of Drug Competition Action Plan, named “Revising ANDA Labeling Following Revision of the RLD Labeling”, providing the recommendations to tentatively approved ANDAs to help facilitate final approval on the earliest lawful... by inpharmedia | Dec 18, 2023 | Blog, Product Development
The Bacterial Endotoxin Test (BET) detects or quantifies endotoxins from gram-negative bacteria using amoebocyte lysate from the horseshoe crab (Limulus polyphemus or Tachypleus tridentatus). Endotoxins are components of gram-negative bacteria’s outer cell... by inpharmedia | Nov 27, 2023 | Approvals, Regulatory
The U.S Food and Drug Administration (FDA) approved OGSIVEO (nirogacestat) for the treatment of progressive desmoid tumors in adults who require systemic treatment. OGSIVEO is the first drug to be approved for the treatment of patients with desmoid tumors, a rare...